Antiangiogenic therapy of brain tumors: the role of bevacizumab.
作者： Elisa Trevisan , Luca Bertero , Chiara Bosa , Michela Magistrello , Alessia Pellerino
DOI: 10.1007/S10072-014-1627-6
关键词: Pathology 、 Cancer research 、 Antiangiogenic therapy 、 Bevacizumab 、 Monoclonal antibody 、 Angiogenesis 、 The Hallmarks of Cancer 、 Vascular proliferation 、 Medicine 、 Tumor growth 、 Neurology
摘要: Angiogenesis is one of the hallmarks cancer, including brain tumors. Malignant gliomas have highest degree vascular proliferation among solid tumors; thus, angiogenic pathways represent an attractive target to interfere with tumor growth. Up date VEGF pathway targeting specific drugs has yielded interesting therapeutics results. In particular bevacizumab, a monoclonal antibody against VEGF-A, shown clinical activity in malignant gliomas, especially glioblastomas, terms high response rate on MRI and significant increase progression-free survival.
springer.com
sci-hub.se 参考文章(69)
Eric T. Wong, Shiva Gautam, Christopher Malchow, Melody Lun, Edward Pan, Steven Brem, Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis Journal of The National Comprehensive Cancer Network. ,vol. 9, pp. 403- 407 ,(2011) , 10.6004/JNCCN.2011.0037
Whitney B. Pope, Jonathan R. Young, Benjamin M. Ellingson, Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy Current Neurology and Neuroscience Reports. ,vol. 11, pp. 336- 344 ,(2011) , 10.1007/S11910-011-0179-X
Antje Wick, Nils Dörner, Navina Schäfer, Silvia Hofer, Sabine Heiland, Daniela Schemmer, Michael Platten, Michael Weller, Martin Bendszus, Wolfgang Wick, Bevacizumab does not increase the risk of remote relapse in malignant glioma. Annals of Neurology. ,vol. 69, pp. 586- 592 ,(2011) , 10.1002/ANA.22336
V. Ranpura, B. Pulipati, D. Chu, X. Zhu, S. Wu, Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis American Journal of Hypertension. ,vol. 23, pp. 460- 468 ,(2010) , 10.1038/AJH.2010.25
Rakesh K. Jain, Emmanuelle di Tomaso, Dan G. Duda, Jay S. Loeffler, A. Gregory Sorensen, Tracy T. Batchelor, Angiogenesis in brain tumours Nature Reviews Neuroscience. ,vol. 8, pp. 610- 622 ,(2007) , 10.1038/NRN2175
Louis M. Sherwood, Edith E. Parris, Judah Folkman, Tumor Angiogenesis: Therapeutic Implications New England Journal of Medicine. ,vol. 285, pp. 1182- 1186 ,(1971) , 10.1056/NEJM197111182852108
Benjamin M. Ellingson, Timothy F. Cloughesy, Albert Lai, Phioanh L. Nghiemphu, Whitney B. Pope, Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-oncology. ,vol. 105, pp. 91- 101 ,(2011) , 10.1007/S11060-011-0567-8
David A. Reardon, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, Anuradha Bulusu, Stevie Threatt, Allan H. Friedman, James J. Vredenburgh, Henry S. Friedman, Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. Journal of Neuro-oncology. ,vol. 107, pp. 155- 164 ,(2012) , 10.1007/S11060-011-0722-2
Karl H. Plate, Werner Risau, Angiogenesis in malignant gliomas Glia. ,vol. 15, pp. 339- 347 ,(1995) , 10.1002/GLIA.440150313
Marc C. Chamberlain, Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas Cancer. ,vol. 116, pp. 3988- 3999 ,(2010) , 10.1002/CNCR.25256